Monarc-M - General Information

Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells


Pharmacology of Monarc-M

Monarc-M binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade.


Monarc-M for patients


Monarc-M Interactions


Monarc-M Contraindications

Known hypersensitivity to mouse protein is a contraindication to the use of Antihemophilic Factor (Human) (AHF), Hemofil M, Method M, Monoclonal Purified.


Additional information about Monarc-M

Monarc-M Indication: For the treatment of hemophilia A, von Willebrand diseae and Factor XIII deficiency
Mechanism Of Action: Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Antihemophilic Factor
Synonyms: AHF; Coagulation factor VIII precursor; Procoagulant component
Drug Category: Coagulants; Thrombotic Agents
Drug Type: Biotech; Approved; Investigational

Other Brand Names containing Antihemophilic Factor: Advate; Alphanate; Bioclate; Helixate; Helixate FS; Hemofil M; Humate-P; Hyate:C; Koate-HP; Kogenate; Kogenate FS; Monarc-M; Monoclate-P;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: 8.4-19.3 hrs
Dosage Forms of Monarc-M: Powder, for solution Intravenous
Chemical IUPAC Name: Not Available
Chemical Formula: C11794H18314N3220O3553S83
Antihemophilic Factor on Wikipedia:
Organisms Affected: Humans and other mammals